1. Home
  2. SABS vs ARDC Comparison

SABS vs ARDC Comparison

Compare SABS & ARDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$2.85

Market Cap

293.9M

Sector

Health Care

ML Signal

N/A

Logo Ares Dynamic Credit Allocation Fund Inc.

ARDC

Ares Dynamic Credit Allocation Fund Inc.

N/A

Current Price

$11.07

Market Cap

274.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SABS
ARDC
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
293.9M
274.2M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
SABS
ARDC
Price
$2.85
$11.07
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $11.64
N/A
AVG Volume (30 Days)
★ 684.9K
149.1K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 78.53
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$11.10
52 Week High
$5.15
$13.74

Technical Indicators

Market Signals
Indicator
SABS
ARDC
Relative Strength Index (RSI) 43.62 32.70
Support Level $2.44 N/A
Resistance Level $4.03 $12.89
Average True Range (ATR) 0.26 0.18
MACD -0.02 -0.04
Stochastic Oscillator 37.58 6.07

Price Performance

Historical Comparison
SABS
ARDC

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

About ARDC Ares Dynamic Credit Allocation Fund Inc.

Ares Dynamic Credit Allocation Fund Inc is a closed-end, diversified, management investment company. The Fund's investment objective is to seek an attractive risk adjusted level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of (i) senior secured loans, (ii) corporate bonds, (iii) other fixed-income instruments, and (iv) securities issued by entities commonly referred to as collateralized loan obligations and other asset-backed securities.

Share on Social Networks: